Scientists identify microRNA as possible cause of chemotherapy resistance

Mar 11, 2010

Scientists may have uncovered a mechanism for resistance to paclitaxel in ovarian cancer, microRNA-31, suggesting a possible therapeutic target for overcoming chemotherapy resistance.

Mohamed K. Hassan, Ph.D., a postdoctoral fellow at Hokkaido University in Japan, completed the research as a collaborative study with his colleagues when he was a professional assistant in South Valley University in Egypt. Results of this study were presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.

"MicroRNAs do not code protein, but they regulate other proteins' expression," said Hassan. "So identifying any as responsible for chemoresistance is, in fact, introducing a real reason for the mechanism."

Ovarian cancer is typically responsive to chemotherapy with , but sometimes cancer cell lines become resistant, which renders useless. Hassan's research team analyzed a set of microRNAs and identified microRNA-31 as being responsible for this chemoresistance. MicroRNA-31 regulates the protein IFITM-1.

"We need to further verify this observation in clinical samples and find a way to inhibit this target protein to improve the effect of paclitaxel and prevent the risk of recurrence," he said.

Explore further: Medical marijuana helpful for cancer-linked symptoms

Related Stories

Double-Duty Nanoparticles Overcome Drug Resistance in Tumors

Jun 14, 2007

Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors ...

Ovarian cancer stem cells identified, characterized

Apr 17, 2008

Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer’s recurrence and its resistance to chemotherapy.

Investigational drug shows promise in ovarian cancer

Sep 15, 2008

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical ...

Recommended for you

Putting the brakes on cancer

4 hours ago

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

4 hours ago

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.